GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Grifols SA (NAS:GRFS) » Definitions » NonCurrent Deferred Liabilities
中文

Grifols (Grifols) NonCurrent Deferred Liabilities : $1,093 Mil (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is Grifols NonCurrent Deferred Liabilities?

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Grifols's non-current deferred liabilities for the quarter that ended in Dec. 2023 was $1,093 Mil.

Grifols NonCurrent Deferred Liabilities Historical Data

The historical data trend for Grifols's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Grifols NonCurrent Deferred Liabilities Chart

Grifols Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 528.00 698.08 733.36 1,112.23 1,093.17

Grifols Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1,112.23 - - 1,093.17

Grifols NonCurrent Deferred Liabilities Related Terms

Thank you for viewing the detailed overview of Grifols's NonCurrent Deferred Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


Grifols (Grifols) Business Description

Industry
Address
Avinguda de la Generalitat, 152-158, Parc de Negocis Can Sant Joan, Sant Cugat del Valles, Barcelona, ESP, 08174
As a vertically integrated plasma derivative producer, Spain-based Grifols collects plasma and then manufactures and sells plasma-derived products globally. By acquiring Talecris in 2011, Grifols dramatically expanded its plasma-derived product portfolio, and the firm's biopharma business contributed 83% of sales in 2022. Grifols also has smaller segments including diagnostics and biosupplies. Diagnostics is roughly 10% of revenue following the Biotest acquisition.

Grifols (Grifols) Headlines

From GuruFocus

David Herro Comments on Grifols

By Sydnee Gatewood 04-14-2022